Zum Hauptinhalt springen

Affinity Biotech

affinity

Founded in 2006, Affinity Biosciences is a pioneering Life Science and High-Tech company whose biochemical products and services are mainly applied in biotechnology, medical research and pharmaceutical development.

Dedicating to advancing customer success through innovation, Affinity Biosciences has established R&D affiliates in the United Kingdom and United States with the aim of providing outstanding service around the globe.Our customers include scientists and technologists in life science companies, university and government institutions, hospitals and industry. To underline our commitment to our customers and enhance our standards of service, we have opened packaging and quality control facilities in the People’s Republic of China. Our goal is to develop high-quality antibody that focuses on Cell Signaling Transduction research, including Akt,AMPK,NF-KappaB,TGF-beta,etc,as well as inhibitors and related reagents.

www.affbiotech.com

The prices are on request! Contact Us by e-mail info@divbio.de

LR3IGF-I, Human, Rapid™ ELISA assay-2 Plate Kit BEK-2233-2P



Der In den Warenkorb Knopf erscheint sobald die obigen Werte ausgewählt wurden

Spezifikationen

2 Plate Kit
Human LR3 insulin-like Growth Factor-I (LR3IGF-I) was developed by GroPep Bioreagents (www.gropep.com) specifically for supplementation of mammalian cell culture to support the survival and proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II and has several advantages over recombinant insulin. Supplementation of cell cultures with LR3IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR3IGF-I is better able to stimulate the type I IGF receptor and thus induce a higher level of activation of intracellular signalling molecules, which are responsible for promoting cell survival by inhibition of apoptosis.

This LR3IGF-I Rapid ELISA kit combines GroPep's many years of expertise in the field of IGF research and Biosensis' newly established Rapid ELISA platform. This collaboration has resulted in the new LR3IGF-I Rapid ELISA kit, which provides for the sensitive, specific and reliable quantification of LR3IGF-I protein in less than 3 hours!

The ELISA kit consists of a complete set of reagents and pre-coated plate to allow immediate assay of LR3IGF-I in culture media. Included in the kit are mouse monoclonal anti- LR3IGF-I capture antibody pre-coated onto an ELISA plate, standard LR3IGF-I protein, a biotinylated anti- LR3IGF-I detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of LR3IGF-I present in samples and the supplied protein standard.

This LR3IGF-I Rapid ELISA kit has been developed, optimized and validated to quantify LR3IGF-I protein in cell culture medium. It is likely to be used to measure LR3IGF-I in media and during downstream processing of media following a production cycle and is not intended for other use. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.